Evidence map›Paper›PMID 35227259›Full record

ArticleTurkish journal of pharmaceutical sciences2022

Resveratrol Delivery

Gurinder Singh

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gurinder SinghMicro Labs GmbH, Frankfurt, GermanyORCID 0000-0003-1525-3898

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resveratrol is a natural compound (an antioxidant) and exhibits numerous therapeutic activities. From a pharmacokinetic perspective, it is unclear whether resveratrol targets the site of action after oral administration because of quick metabolism and excretion that creates doubt on the biological application of the high doses characteristically used for clinical trials. However, these limitations act as a barrier and a challenge for the development of new delivery systems. Recently, gene delivery offers various advantages and has provided treatment options for diseases that are beyond the reach of traditional approaches. The objective of gene therapy for genetic diseases is to achieve durable expression of the therapeutic gene at a level sufficient to alleviate or cure disease symptoms with minimal adverse events. The perception of the molecular and cellular mechanisms steering to therapy and vector-related hindrances have caused in the progress of extremely complex gene delivery with enhanced protection and effectiveness. With the help of gene therapy, it could be possible to target the delivery of resveratrol directly into the host cells and bypass its pharmacokinetic limitations and enhancement of its therapeutic effect. This review is to provide a holistic view of the development of resveratrol gene treatment as a powerful option to treat various deadly diseases.

Indexed as

Gene therapy/deliverylentivirusresveratrolviral vectors

Identifiers

PMID35227259
PMCPMC8892559
OpenAlexW3094616087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.